Cure
Overview
From self-amplifying RNA to programmable, cell-selective therapies, a new class of biotech companies is pushing mRNA beyond vaccines and into precision medicine across cancer, rare disease, and chronic conditions.
The initial COVID-19 vaccines introduced messenger RNA (mRNA) technology to the world, but the field is now rapidly accelerating beyond that foundational beginning. The technology's success, demonstrated through its flexibility and speed, has transformed the primary goal for researchers from prioritizing a fast emergency response to focusing on advanced, next-generation innovations.
This rapid change is happening because mRNA is an "information-based platform," as Moderna CEO Stéphane Bancel described in an interview with McKinsey, "working similar to a computer’s operating system" that allows scientists to quickly add new genetic code. These efforts now focus on making delivery more efficient, extending the therapeutic effect, and broadening the scope across different medical areas, including infectious diseases, cancer, rare genetic conditions, and autoimmune disorders.
“The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed, and manufactured,” Bancel says.
A sophisticated new wave of platforms is entering clinical testing, such as self-amplifying mRNA (srRNA), circular RNA (oRNA), and cell-selective mRNA. This clinical progress, combined with many new industry collaborations, shows that mRNA is quickly changing from a simple tool into a flexible, mature system. It is now capable of precision medicine for a wide variety of illnesses, from customized cancer therapies to managing chronic disease.
Our curated list focuses on organizations that are actively developing their own proprietary mRNA platforms and advancing their programs beyond the first generation of COVID-era technology. This includes key innovators focused on new lipid nanoparticle (LNP) delivery systems, programmable therapeutic circuits, and new RNA formats that are defining the future of genetic medicine.
Although hundreds of companies are exploring the potential of mRNA, we have selected nine that stand out due to ambitious science, clinical traction, or platform promise.
Alltrna
Sector: Transfer RNA (tRNA) medicines
HQ: Cambridge, MA
Year Founded: 2018
Origin Story: Founded within Flagship Pioneering to develop a programmable transfer RNA platform capable of correcting premature termination codon mutations, with the goal of treating thousands of genetic diseases driven by shared stop-codon errors.
Key Leaders: Joanne Protano, President and CEO; Dave Hava, PhD, Chief Scientific Officer; Nerissa Kreher, Chief Medical Officer; William Kiesman, PhD, Chief Technology Officer
Number of Employees: ~50
Stage: Private
Key Investors: Founded and backed by Flagship Pioneering, which provided an initial commitment of roughly $50 million to launch the platform, and participated in a major Series B financing.
Financial Snapshot: Alltrna completed a $109 million Series B financing in August 2023 to advance its tRNA therapeutic platform and first drug candidates towards clinical development, with participation from Flagship Pioneering and other investors.
Key Products: The company offers a programmable transfer RNA (tRNA) platform engineered to correct premature termination codon (PTC) mutations and restore full-length protein production. Its platform is designed to treat thousands of genetic diseases driven by shared stop-codon mutations by enabling engineered tRNAs to read through these errors and restore correct protein expression.
Recent Highlights: In December 2024, Alltrna presented preclinical proof-of-concept data for its first tRNA development candidate, AP003, showing in vivo restoration of protein production in two transgenic mouse models of stop codon disease following a single dose.
Arcturus Therapeutics
Sector: RNA medicines
HQ: San Diego, CA
Year Founded: 2013
Origin Story: Founded to advance RNA medicines through proprietary delivery and amplification technologies, including the LUNAR lipid nanoparticle system and STARR self-amplifying mRNA platform, targeting both infectious diseases and rare genetic conditions.
Key Leaders: Joseph Payne, President and CEO; Padmanabh “Pad” Chivukula, Chief Scientific Officer and COO; Alan H. Cohen, MD, Chief Medical Officer
Number of Employees: ~110
Stage: Public
Financial Snapshot: The company’s market cap was $0.21 Billion USD as of March 2026.
Key Products: The company offers proprietary RNA platforms including the LUNAR lipid delivery system and STARR self-amplifying mRNA technology. Arcturus develops vaccines and therapeutics using these platforms, including mRNA-based vaccines for COVID-19, influenza (seasonal and pandemic), and RNA therapeutic candidates for cystic fibrosis and ornithine transcarbamylase deficiency.
Recent Highlights: In October 2025, Arcturus reported Phase 2 interim data for ARCT-032, its inhaled mRNA therapy for cystic fibrosis, and announced plans to initiate a 12-week safety and efficacy study in the first half of 2026. The company is also advancing ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase deficiency, alongside KOSTAIVE, its self-amplifying COVID-19 vaccine approved in Japan and the European Union.
Kernal Biologics
Sector: Programmable messenger RNA (mRNA) therapeutics
HQ: Cambridge, MA
Year Founded: 2016
Origin Story: Founded to build a cell-selective mRNA platform that uses artificial intelligence to design therapeutics activated only within specific cell types, enabling precision oncology applications such as in vivo CAR-T programming.
Key Leaders: Yusuf Erkul, MD, CEO and Co-Founder; Burak Yilmaz, President and Co-Founder; Manfred Kraus, PhD, SVP and Head of R&D Therapeutics
Number of Employees: ~18
Stage: Private, Series A
Key Investors: Hummingbird Ventures, Amgen Ventures, HBM Genomics, Civilization Ventures, Y Combinator, and FoundersX
Financial Snapshot: Kernal Biologics closed a $25 million Series A round in February 2022, led by Hummingbird Ventures, bringing total funding raised to more than $35 million.
Key Products: The company provides a cell-selective mRNA platform that uses artificial intelligence (AI) to design therapeutics activated only in specific cell types. Kernal develops oncology programs, including mRNA-encoded Chimeric Antigen Receptor T-cell (CAR-T) therapies, and supports delivery optimization and safety in advanced cancer applications.
Recent Highlights: In October 2025, ARPA-H awarded Kernal Bio up to $48 million to support clinical development of KR-402, its in vivo mRNA-encoded CAR-T cell program targeting multiple sclerosis and B-cell malignancies. That same month, the company joined Lilly Gateway Labs in Boston, gaining access to lab space and Lilly's global network of scientific experts.
Replicate Bioscience
Sector: Self-replicating RNA (srRNA) therapeutics
HQ: San Diego, CA
Year Founded: 2020
Origin Story: Founded to harness self-replicating RNA technology to achieve sustained protein expression at significantly lower doses, reducing the burden of vaccination and expanding access to effective RNA-based medicines.
Key Leaders: Nathaniel Wang, PhD, CEO and Co-Founder; Andrew Geall, PhD, Chief Development Officer and Co-Founder; Kathy Fernando, PhD, Chief Business Officer; Parinaz Aliahmad, PhD, Chief Scientific Officer
Number of Employees: ~20
Stage: Private, Series B
Key Investors: Apple Tree Partners, Novo Nordisk
Financial Snapshot: Raised at least $40 million in initial Series A capital provided by Apple Tree Partners to support platform development. Under a collaboration with Novo Nordisk, Replicate is eligible to receive up to approximately $550 million in research funding and milestone payments, plus tiered royalties on future product sales.
Key Products: The company offers a proprietary self-replicating RNA (srRNA) platform driving sustained protein expression at lower doses, with advanced candidates such as srRNA vaccine RBI-4000, a rabies vaccine candidate, showing protective immunity at reduced dose levels in Phase 1 trials.
Recent Highlights: In February 2025, Replicate published Phase 1 data for RBI-4000, its srRNA rabies vaccine candidate, in Nature Communications, providing the first peer-reviewed clinical evidence of protective immunity achieved at reduced dose levels. In August 2025, the company announced a multi-year collaboration with Novo Nordisk to develop srRNA-based therapeutics for cardiometabolic diseases, including obesity and type 2 diabetes.
Sail Biomedicines
Sector: Endless RNA (eRNA) therapeutics and programmable RNA medicines
HQ: Cambridge, MA
Year Founded: 2023
Origin Story: Formed through the merger of Flagship Pioneering companies Laronde and Senda Biosciences to combine Endless RNA technology with targeted nanoparticle delivery, enabling programmable RNA medicines across a broad range of diseases.
Key Leaders: John Mendlein, PhD, Executive Chairman; Vincent Hennemand, PhD, Chief Product and Operations Officer
Number of Employees: ~110
Stage: Private, preclinical/platform-stage
Key Investors: Sail Biomedicines was formed in October 2023 through the combination of Laronde and Senda Biosciences, both Flagship Pioneering companies. Additional investors include T. Rowe Price, BlackRock, Fidelity Management & Research Company, and the Bill & Melinda Gates Foundation.
Financial Snapshot: Sail was formed from the merger of Laronde, which had raised $490 million across its Series A and B rounds, and Senda Biosciences. Flagship Pioneering and the institutional investors who participated in Laronde's prior financing rounds are among the combined company's primary backers. Exact total funding for the merged entity has not been publicly disclosed.
Key Products: Sail's platform enables programmable pharmacology with translatable circular RNA technology — Endless RNA (eRNA) — and programmable deployment via targeted nanoparticles (TNPs) equipped with disease-specific targeting ligands. By leveraging rapid prototyping and proprietary AI algorithms, Sail integrates the design of RNA medicines across metabolic disease, rare disease, immuno-oncology, infectious diseases, and autoimmune disorders.
Recent Highlights: In early 2024, Sail received grants from the Bill & Melinda Gates Foundation to advance its eRNA platform toward the development of secreted monoclonal antibodies and malaria vaccines. The company is also advancing preclinical programs in cystic fibrosis in collaboration with the Cystic Fibrosis Foundation.
Shape Therapeutics
Sector: RNA editing and messenger RNA (mRNA) medicine platforms
HQ: Seattle, WA
Year Founded: 2018
Origin Story: Founded to develop programmable RNA editing tools that correct disease-causing mutations at the RNA level, using endogenous ADAR enzymes to make precise sequence corrections without permanently altering the genome.
Key Leaders: Prashant Mali, Co-Founder and Board Director; Ed Mathers, General Partner, New Enterprise Associates, Board Director
Number of Employees: ~85
Stage: Private, Series B
Key Investors: Cherubic Ventures, Decheng Capital, Willett Advisors, Breton Capital Ventures, CureDuchenne Ventures
Key Products: Programmable RNA editing platform RNAfix for precision RNA sequence correction via Adenosine Deaminase Acting on RNA (ADAR) recruitment. AI-driven design of novel RNA payloads and engineered viral delivery vectors. TruStable manufacturing platform for scalable viral vector (adeno-associated virus (AAV)) production.
Financial Snapshot: Completed a $112 million Series B financing co-led by Decheng Capital and Breton Capital (2021), bringing total known capital raised to approximately $147.5 million at that time.
Recent Highlights: In September 2025, Shape Therapeutics announced an option and license agreement with VectorY Therapeutics, worth up to $1.2 billion, to advance vectorized antibodies for neurodegenerative diseases. That same month, the company presented preclinical data showing its lead Parkinson's disease program, SHP-201, achieved more than 70 percent reduction of targeted alpha-synuclein in the non-human primate brain following intravenous administration.
Strand Therapeutics
Sector: Programmable messenger RNA (mRNA) therapeutics
HQ: Boston, MA
Year Founded: 2017
Origin Story: Founded to engineer synthetic gene circuits within mRNA, enabling programmable control of immune signaling inside tumors and expanding the therapeutic potential of mRNA beyond simple protein replacement.
Key Leaders: Jake Becraft, Co-Founder and CEO; Tasuku Kitada, Co-Founder; Ron Weiss, Co-Founder
Number of Employees: ~110
Stage: Private, clinical-stage
Key Investors: Alderline Group, Alix Ventures, Gradiant, Kinnevik, Regeneron Ventures, Amgen Ventures, Eli Lilly and Company, FPV Ventures, Playground Global, ANRI, Potentum, and ICONIQ.
Financial Snapshot: Strand Therapeutics closed a $153 million Series B financing round led by Kinnevik, with participation from Regeneron Ventures, Amgen Ventures, Eli Lilly and Company, FPV Ventures, Playground Global, ANRI, Potentum, ICONIQ and others, bringing total funding to over $250 million and an estimated valuation near $550 million.
Key Products: The company provides a programmable mRNA platform that enables synthetic gene circuits to control immune signaling within tumors. Its lead product, STX-001, is an oncology therapy designed to safely modulate tumor microenvironments, and the platform supports the development of additional programmable RNA therapeutics.
Recent Highlights: At the 2025 ASCO Annual Meeting, Strand presented Phase 1 data for STX-001 in 22 people with checkpoint inhibitor-refractory solid tumors, reporting multiple responses including a confirmed complete response and a favorable safety profile. In August 2025, the company closed a $153 million Series B financing round led by Kinnevik to advance STX-001 and support the planned first-in-human entry of STX-003 in 2026.
Orbital Therapeutics
Sector: RNA medicines (circular RNA, immunotherapy)
HQ: Cambridge, MA
Year Founded: 2022
Origin Story: Founded to integrate circular RNA technology, targeted delivery, data science, and automation into a unified platform, with initial programs aimed at reprogramming immune cells in vivo for autoimmune disease and cancer.
Key Leaders: Ron Philip, President and Chief Executive Officer; Gilles Besin, Ph.D., Chief Scientific Officer. Co-founders include Giuseppe Ciaramella, Ph.D., Scientific and Strategic advisor, and John Maraganore, Ph.D., Chairman of the Board.
Number of Employees: ~70
Stage: Acquired by Bristol Myers Squibb
Financial Snapshot: The company was acquired by Bristol Myers Squibb in October 2025 for $1.5 billion in cash at closing.
Key Products: Orbital is developing a platform designed to integrate RNA technology, delivery methods, data science, and automation, with initial programs focused in vaccines, immunomodulation, protein replacement, and regenerative medicine. Its lead candidate, OTX-201, uses lipid nanoparticle-delivered circular RNA to reprogram T cells in vivo for the treatment of autoimmune disease.
Recent Highlights: In July 2025, Orbital presented preclinical data for OTX-201 demonstrating that its in vivo CAR-T approach achieved full B cell depletion in blood, spleen, and lymph nodes in a non-human primate study. The company is advancing OTX-201 through IND-enabling studies and plans to initiate clinical development in the first half of 2026.
